A major milestone in neurogenetic medicine has just been reached. Researchers in the UK, led by University College London (UCL) Queen Square Institute of Neurology and the biotech company uniQure, have announced that a one‐time gene therapy, which is called AMT‑130, has resulted in a reported 75 % slowing of disease progression in patients with early‐stage Huntington disease over a 36 month period.
Huntington disease (HD) is a devastating, inherited neurodegenerative disorder caused by a mutation in the HTT gene, which results in the build-up of a toxic form of the huntingtin protein. Over time, this leads to neuronal death in key brain regions, and to the progressive loss of motor, cognitive and psychiatric function. Until now, all available therapies have been symptomatic only. Nothing had convincingly altered the underlying disease trajectory.
The trial in question is a Phase I/II study, enrolling 29 patients (12 of whom received the high-dose form of AMT-130). Patients in the high-dose arm demonstrated the markedly slower decline in function compared to historical control cohorts. Importantly, there was also a significant reduction in a neurodegeneration biomarker (neurofilament light chain) in cerebrospinal fluid, supporting that neuronal damage was being attenuated.
From a genetics perspective the mechanism is elegant. The therapy uses a viral vector delivered directly into the brain (via stereotactic neurosurgical infusion) into regions of the striatum. The vector carries DNA encoding a microRNA sequence which binds to mutant huntingtin mRNA and triggers its degradation, thereby reducing the production of the toxic protein at source. In short, this is gene therapy in the truest sense: one dose, permanent change in neuronal gene expression.
For Rosalind Genetics and our focus on precision medicine and genetic counselling, this is hugely relevant. Here are key take-aways:
- Disease-modifying gene therapy is real now: This study marks perhaps the first time a neurodegenerative condition with a clear monogenic cause has been convincingly slowed by a gene therapy.
- Implications for counselling and testing: For individuals who carry or are at risk of developing HD, this shifts the paradigm from “no treatment, only monitoring” to “there may be a treatment on the horizon”. That will influence decisions around predictive testing, family planning, psychological support, and referral pathways.
- Ethical, access and cost issues loom: Although the results are exciting, the therapy involves major brain surgery and is likely to be extremely costly initially. Accessibility, equity of access, and long-term follow-up will be important. Experts caution we are still at “early days.”
- Model for other monogenic neuro-disorders: The success of AMT-130 suggests that gene therapy can work even in complex brain conditions. It opens the door for other rare inherited neurological diseases.
- What it means for service providers: As a genetic-counselling company, we must keep abreast of such therapeutic advances because they affect patient pathways, testing demand, risk-benefit discussions, and collaboration with clinical trials and industry.
Of course, caveats remain. The data are still preliminary; the full peer-reviewed publication is pending. And long-term safety (10-20 years) is unknown. The trial used direct brain delivery, so scalability and cost will be challenging. But if approved, AMT-130 could become the first licensed treatment to slow Huntington disease, a transformative moment for patients and families.
In short: this is a watershed moment in gene therapy and hereditary neurological disorders. At Rosalind Genetics we will be watching the regulatory progress of AMT-130 closely, integrating such developments into our counselling frameworks, and ensuring that our clients and their families receive informed, up-to-date guidance about the evolving therapeutic landscape.
